Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)
NCT05136456 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)
- Lead sponsor
- Reistone Biopharma Company Limited
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 15, 2021
- Completion date
- March 11, 2024
- Enrollment
- 61 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
primary membranous nephropathy